Interleukin 5 News and Research

RSS

Bacterium that causes Q fever associated with increased risk of lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.

13 Oct 2015

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Novartis announced today new late-breaking data demonstrating that CosentyxTM provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.

13 Oct 2015

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

Provepep, the peptide business unit of Provence Technologies Group, a specialist fine chemistry research group, today announces that it has successfully synthesized tens of mg of bioactive homodimer form of IL-10.

7 Oct 2015

Immune system protein has potential to prevent onset of aggressive form of rheumatoid arthritis

Scientists have discovered what they believe has the potential to prevent the onset of an aggressive and hard-to-treat form of rheumatoid arthritis - a condition that affects 700,000 adults in the UK.

7 Oct 2015

IU-led scientists discover new gene that increases Alzheimer's disease risk

In a newly published study, a multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer's patients and older adults at risk for the disease.

6 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Type-2 diabetes medication can affect the brain's reward system, reduce intake of food

Many studies have focused on how much we eat when we are hungry, but sometimes we eat just to feel better. A new dissertation at Sahlgrenska Academy shows that medication used for type-2 diabetes wich mimics the gut-brain hormone glucagon-like peptide-1, can affect the brain's reward system and reduce the intake of food.

29 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

Inflammatory response could be key link between dietary fats and obesity-related diseases

An enhanced inflammatory response could be the key link between high saturated fat intake - a recognized risk factor for obesity-related disorders - and the development of diseases like type 2 diabetes and atherosclerosis.

26 Sep 2015

Pipetting Solutions for Sample Screening

Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.

From INTEGRA Biosciences 16 Sep 2015

Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Revealing a biological combat strategy worthy of a five-star general, researchers from Houston Methodist Hospital, University of Chicago and Cornell University have shown how a cell surface receptor--a specialized protein which communicates signals between a cell and the outside world--can mobilize immune cells to attack, rather than protect, malignant tumors.

15 Sep 2015

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

15 Sep 2015

New molecule shows efficacy in inhibiting inflammation, preventing premature delivery in murine models

Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models - without adversely affecting the fetus or the mother.

9 Sep 2015

Scientists discover mechanism that could lead to new treatment for allergies

Most people with allergies have to take medication throughout their life: Their body "thinks" that proteins from the environment are so "strange" that they elicit an immune reaction. Until present, it was not possible to develop an efficient therapy so that the body "learns" to stop in an overreacting way.

8 Sep 2015

Regulatory T cells may reduce susceptibility to allergies

Susceptibility to allergies reduced by increased production of regulatory T cells. This is the main finding of a current study being conducted at the Institute of Immunology at MedUni Vienna, headed up by Winfried F. Pickl. The initial results of this study by Alina Neunkirchner, which looks at the root cause of the development of allergies, are being presented at the European Congress of Immunology, which starts in Vienna this Sunday (6 - 9 September 2015, Austria Center Vienna).

3 Sep 2015

Researchers uncover important cellular functions that help regulate inflammation

Researchers at the Virginia Bioinformatics Institute at Virginia Tech have uncovered key cellular functions that help regulate inflammation -- a discovery that could have important implications for the treatment of allergies, heart disease, and certain forms of cancer.

28 Aug 2015

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.

26 Aug 2015

Karolinska Institutet study may lead to development of better immune-based cancer therapies

A study by researchers at Sweden's Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells. The results, which are being published in the 'Journal of the National Cancer Institute', can contribute to the development of better immune-based cancer therapies.

25 Aug 2015

Early exposure to inflammatory cytokines can paralyze CD4 T cells

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help orchestrate the body's response to pathogens and other invaders.

19 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015